Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Cross

Showing results (431-440 of 595) with videos related to

Pageof 60
Sort By:
Health Technology Assessment (Winchester, England)|May 29, 2008
Topical or oral ibuprofen for chronic knee pain in older people. The TOIB studyM Underwood, D Ashby, D Carnes, et al.
Leukemia|February 27, 2014
A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemiaM W Drummond, C Pocock, M Boissinot, et al.
Annals of Hematology|September 27, 2012
Activating CBL mutations are associated with a distinct MDS/MPN phenotypeJuliana Schwaab, Thomas Ernst, Philipp Erben, et al.
American Journal of Hematology|May 29, 2015
KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significanceJuliana Schwaab, Roland Umbach, Georgia Metzgeroth, et al.
Nature Genetics|March 17, 2009
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasmsAmy V Jones, Andrew Chase, Richard T Silver, et al.
Haematologica|February 25, 2015
Low frequency mutations independently predict poor treatment-free survival in early stage chronic lymphocytic leukemia and monoclonal B-cell lymphocytosisNils Winkelmann, Matthew Rose-Zerilli, Jade Forster, et al.
International Journal of Cancer|November 4, 2004
Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 yearsMartin J Slade, Anjana Singh, Brendan M Smith, et al.
Leukemia Research|December 16, 2014
Evaluation of methods to detect CALR mutations in myeloproliferative neoplasmsAmy V Jones, Daniel Ward, Matthew Lyon, et al.
Annals of Hematology|April 3, 2023
Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysisJohannes Lübke, Nicole Naumann, Georgia Metzgeroth, et al.
Blood|April 21, 2017
Response and progression on midostaurin in advanced systemic mastocytosis: <i>KIT</i> D816V and other molecular markersMohamad Jawhar, Juliana Schwaab, Nicole Naumann, et al.
Pageof 60

Showing results (431-440 of 595) with videos related to

Sort By:
Pageof 60
Health Technology Assessment (Winchester, England)|May 29, 2008
Topical or oral ibuprofen for chronic knee pain in older people. The TOIB studyM Underwood, D Ashby, D Carnes, et al.
Leukemia|February 27, 2014
A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemiaM W Drummond, C Pocock, M Boissinot, et al.
Annals of Hematology|September 27, 2012
Activating CBL mutations are associated with a distinct MDS/MPN phenotypeJuliana Schwaab, Thomas Ernst, Philipp Erben, et al.
American Journal of Hematology|May 29, 2015
KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significanceJuliana Schwaab, Roland Umbach, Georgia Metzgeroth, et al.
Nature Genetics|March 17, 2009
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasmsAmy V Jones, Andrew Chase, Richard T Silver, et al.
Haematologica|February 25, 2015
Low frequency mutations independently predict poor treatment-free survival in early stage chronic lymphocytic leukemia and monoclonal B-cell lymphocytosisNils Winkelmann, Matthew Rose-Zerilli, Jade Forster, et al.
International Journal of Cancer|November 4, 2004
Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 yearsMartin J Slade, Anjana Singh, Brendan M Smith, et al.
Leukemia Research|December 16, 2014
Evaluation of methods to detect CALR mutations in myeloproliferative neoplasmsAmy V Jones, Daniel Ward, Matthew Lyon, et al.
Annals of Hematology|April 3, 2023
Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysisJohannes Lübke, Nicole Naumann, Georgia Metzgeroth, et al.
Blood|April 21, 2017
Response and progression on midostaurin in advanced systemic mastocytosis: <i>KIT</i> D816V and other molecular markersMohamad Jawhar, Juliana Schwaab, Nicole Naumann, et al.
Pageof 60